$0.91
0.05% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Hoth Therapeutics, Inc. Stock price

$0.91
-0.31 25.37% 1M
+0.18 24.73% 6M
+0.16 21.71% YTD
-0.36 28.31% 1Y
-13.34 93.61% 3Y
-100.84 99.11% 5Y
-212.34 99.57% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.03 3.59%
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Key metrics

Market capitalization $11.97m
Enterprise Value $3.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.84
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-7.53m
Free Cash Flow (TTM) Free Cash Flow $-8.02m
Cash position $8.02m
EPS (TTM) EPS $-1.40
P/E forward negative
Short interest 4.76%
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Hoth Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
100%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.69 4.69
101% 101%
-
- Research and Development Expense 2.84 2.84
48% 48%
-
-7.53 -7.53
32% 32%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -7.53 -7.53
32% 32%
-
Net Profit -7.51 -7.51
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
18 days ago
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montr...
Neutral
PRNewsWire
about one month ago
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2...
Neutral
PRNewsWire
about one month ago
IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline. These newly secured pate...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 6
Founded 2017
Website www.hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today